Antisense Technology

Exclusive Worldwide License to Technology Obtained

Published in Cancer Weekly, September 30th, 1996

Cytoclonal Pharmaceutics Inc., Dallas, Texas, announced that it has obtained an exclusive worldwide license to the antisense technology developed at the University of Texas at Dallas through contract research supported by Cytoclonal.

Under a collaborative research agreement with the University, Cytoclonal exercised its first rights of refusal for the technology. Antisense products are under development to control genes involved in human diseases such as cancer, diabetes, or AIDS.

Antisense products bind to the disease related gene material to prevent it from causing the disease. Multiple human genes have been shown to be involved in human disease...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1996-09-30)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry